Rev. OFIL 2017, 27;2:207-209
Fecha de recepción: 07/06/2016 – Fecha de aceptación: 24/08/2016
Llorente Serrano M1, Valera Rubio M2, Busto Medina MJ3, Barreda Hernández D4
1 Farmacéutico Interno Residente
2 Especialista en Farmacia Hospitalaria
3 Médico Especialista en Hematología
4 Jefe de Servicio de Farmacia
Servicio de Farmacia. Hospital Virgen de la Luz. Gerencia de Atención Integrada de Cuenca (España)
Correspondencia:
Marta Llorente Serrano
C/Hermandad Donantes de Sangre, s/n
16002 Cuenca
Correo electrónico: martallose@gmail.com
____
SUMMARY
New direct action antiviral drugs are a cure in many cases of chronic hepatitis C (CHC). They show a good safety profile in clinical trials.
We describe the case of a patient with CHC who developed severe thrombocytopenia two weeks after ombitasvir/paritaprevir/ritonavir and dasabuvir treatment was started.
The platelets counts presented complete recovery when antiviral therapy discontinued.
Thrombocytopenia is not considered as an adverse effect of these drugs. However a possible causal relationship could be established in this case.
Key Words: Hepatitis C, direct acting antivirals, ombitasvir, paritaprevir, dasabuvir, thrombocytopenia, adverse events.
____
Download PDF: Posible trombopenia por ombitasvir, paritaprevir y dasabuvir en hepatitis C. A propósito de un caso